Literature DB >> 12353204

Treatment of uncomplicated genital Chlamydia trachomatis infections in adults.

Adaora A Adimora1.   

Abstract

To prepare the 2001 sexually transmitted disease treatment guidelines of the Centers for Disease Control and Prevention, recently published articles and abstracts concerning advances in the treatment of uncomplicated Chlamydia trachomatis genital infections in adults were reviewed. Questions about treatments were posed and answered according to the results of efficacy studies and clinical trials. Recent studies have continued to demonstrate the similar efficacy of doxycycline and azithromycin. Because compliance with doxycyline remains a concern, administration of single-dose azithromycin therapy in the clinic presents a potential advantage for patients whose adherence is questionable. Because few systematically collected data have been published concerning the safety and efficacy of azithromycin use in pregnancy, the guidelines continue to recommend treatment with erythromycin or amoxicillin. Nevertheless, because of azithromycin's less frequent side effects and improved adherence, increasing numbers of obstetricians in the United States are using azithromyin to treat pregnant women with uncomplicated C. trachomatis infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353204     DOI: 10.1086/342105

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.

Authors:  Manuela Donati; Antonietta Di Francesco; Antonietta D'Antuono; Federica Delucca; Alisa Shurdhi; Alessandra Moroni; Raffaella Baldelli; Roberto Cevenini
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 2.  [Reactive arthritis: from pathogenesis to novel strategies].

Authors:  M Rihl; J G Kuipers
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 3.  [Update on reactive arthritis].

Authors:  M Rihl
Journal:  Z Rheumatol       Date:  2016-11       Impact factor: 1.372

4.  Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.

Authors:  Ronald N Jones; Douglas J Biedenbach; Patricia M Roblin; Stephan A Kohlhoff; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

5.  Chlamydia and gonorrhoea in pregnancy: effectiveness of diagnosis and treatment in Botswana.

Authors:  M Romoren; M Rahman; J Sundby; P Hjortdahl
Journal:  Sex Transm Infect       Date:  2004-10       Impact factor: 3.519

6.  Public health policies and management strategies for genital Chlamydia trachomatis infection.

Authors:  Kelly Shaw; David Coleman; Maree O'Sullivan; Nicola Stephens
Journal:  Risk Manag Healthc Policy       Date:  2011-05-19

7.  Pregnancy outcome following gestational exposure to azithromycin.

Authors:  Moumita Sarkar; Cindy Woodland; Gideon Koren; Adrienne R N Einarson
Journal:  BMC Pregnancy Childbirth       Date:  2006-05-30       Impact factor: 3.007

8.  Doxycycline inhibits leukemic cell migration via inhibition of matrix metalloproteinases and phosphorylation of focal adhesion kinase.

Authors:  Chunhuai Wang; Ru Xiang; Xiangzhong Zhang; Yunxian Chen
Journal:  Mol Med Rep       Date:  2015-05-25       Impact factor: 2.952

9.  Could a simple antenatal package combining micronutritional supplementation with presumptive treatment of infection prevent maternal deaths in sub-Saharan Africa?

Authors:  Simon M Collin; Rebecca F Baggaley; Rudiger Pittrof; Veronique Filippi
Journal:  BMC Pregnancy Childbirth       Date:  2007-05-23       Impact factor: 3.007

10.  Azithromycin prevents pregnancy loss: reducing the level of tumor necrosis factor-alpha and raising the level of interleukin-10 in rats.

Authors:  Ayse Er
Journal:  Mediators Inflamm       Date:  2013-11-24       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.